Search for common targets of lithium and valproic acid identifies novel epigenetic effects of lithium on the rat leptin receptor gene

Translational Psychiatry

Volumn 5, Issue 7, 2015, Pages

  Lee, R S ^a   Pirooznia, M ^a   Guintivano, J ^a,b   Ly, M ^a   Ewald, E R ^a   Tamashiro, K L ^a   Gould, T D ^b   Moran, T H ^a   Potash, J B ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; HISTONE H3; LEPTIN RECEPTOR; LITHIUM; MESSENGER RNA; VALPROIC ACID; LITHIUM DERIVATIVE; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL GENETICS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; BRAIN CELL; BROWN NORWAY RAT; CHROMATIN; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DRUG TARGETING; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; HIPPOCAMPAL TISSUE; HISTONE METHYLATION; LEPTIN RECEPTOR GENE; MALE; MICROARRAY ANALYSIS; NONHUMAN; PROMOTER REGION; PROTEIN ACETYLATION; PYROSEQUENCING; RAT; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; DNA MICROARRAY; DRUG EFFECTS; GENE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENES; LITHIUM COMPOUNDS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, INBRED BN; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, LEPTIN; TRANSCRIPTOME; VALPROIC ACID;

EID: 84990934016     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.90     Document Type: Article

References (71)

1. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011; 68: 241-251.
2. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA 1999; 96: 8745-8750.
3. De Sarno P, Li X, Jope RS.. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 2002; 43: 1158-1164.
4. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459.
5. Popkie AP, Zeidner LC, Albrecht AM, D'Ippolito A, Eckardt S, Newsom DE et al. Phosphatidylinositol 3-kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci. J Biol Chem 2010; 285: 41337-41347.
6. Wu S, Zheng SD, Huang HL, Yan LC, Yin XF, Xu HN et al. Lithium down-regulates histone deacetylase 1 (HDAC1) and induces degradation of mutant huntingtin. J Biol Chem 2013; 288: 35500-35510.
7. Kwon B, Houpt TA.. Phospho-acetylation of histone H3 in the amygdala after acute lithium chloride. Brain Res 2010; 1333: 36-47.
8. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72: 1327-1330.
9. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS.. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-36741.
10. Milutinovic S, D'Alessio AC, Detich N, Szyf M. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 2007; 28: 560-571.
11. Gould TD, Quiroz JA, Singh J, Zarate CA, Manji HK. Emerging experimental therapeutics for bipolar disorder: Insights from the molecular and cellular actions of current mood stabilizers. Mol Psychiatry 2004; 9: 734-755.
12. Gould TD, Chen G, Manji HK. Mood stabilizer psychopharmacology. Clin Neurosci Res 2002; 2: 193-212.
13. National Research Council. Guide for the Care and Use of Laboratory Animals. 8th edn, National Academies Press: Washington, DC, USA, 2011 xxv 220 p.
14. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-193.
15. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31: E15.
16. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3, Article3.
17. Wettenhall JM, Simpson KM, Satterley K, Smyth GK. affylmGUI: A graphical user interface for linear modeling of single channel microarray data. Bioinformatics 2006; 22: 897-899.
18. Huang, da W, Sherman BT, Tan Q, Kir J, Liu D, Bryant D et al. DAVID Bioinformatics Resources: Expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 2007; 35: W169-W175.
19. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003; 35: 146-150.
20. Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489-1493.
21. Goodman LS, Brunton LL, Chabner B, Knollmann BrC. Goodman & Gilman's Pharmacological Basis of Therapeutics. 12th edn, McGraw-Hill: New York, USA, 2011, p 2084.
22. Gould TD, O'Donnell KC, Picchini AM, Manji HK. Strain differences in lithium attenuation of d-amphetamine-induced hyperlocomotion: A mouse model for the genetics of clinical response to lithium. Neuropsychopharmacology 2007; 32: 1321-1333.
23. van Enkhuizen J, Geyer MA, Kooistra K, Young JW. Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice. Int J Neuropsychopharmacol 2013; 16: 1021-1031.
24. Nakao M, Bono H, Kawashima S, Kamiya T, Sato K, Goto S et al. Genome-scale gene expression analysis and pathway reconstruction in KEGG. Genome Inform Ser Workshop Genome Inform 1999; 10: 94-103.
25. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 1999; 27: 29-34.
26. Pan JQ, Lewis MC, Ketterman JK, Clore EL, Riley M, Richards KR et al. AKT kinase activity is required for lithium to modulate mood-related behaviors in mice. Neuropsychopharmacology 2011; 36: 1397-1411.
27. Garza JC, Guo M, Zhang W, Lu XY. Leptin restores adult hippocampal neurogenesis in a chronic unpredictable stress model of depression and reverses glucocorticoid-induced inhibition of GSK-3beta/beta-catenin signaling. Mol Psychiatry 2012; 17: 790-808.
28. Guo M, Huang TY, Garza JC, Chua SC, Lu XY. Selective deletion of leptin receptors in adult hippocampus induces depression-related behaviours. Int J Neuropsychopharmacol 2013; 16: 857-867.
29. Kloiber S, Ripke S, Kohli MA, Reppermund S, Salyakina D, Uher R et al. Resistance to antidepressant treatment is associated with polymorphisms in the leptin gene, decreased leptin mRNA expression, and decreased leptin serum levels. Eur Neuropsychopharmacol 2013; 23: 653-662.
30. Lawson EA, Miller KK, Blum JI, Meenaghan E, Misra M, Eddy KT et al. Leptin levels are associated with decreased depressive symptoms in women across the weight spectrum, independent of body fat. Clin Endocrinol (Oxf) 2012; 76: 520-525.
31. Liu J, Perez SM, Zhang W, Lodge DJ, Lu XY. Selective deletion of the leptin receptor in dopamine neurons produces anxiogenic-like behavior and increases dopaminergic activity in amygdala. Mol Psychiatry 2011; 16: 1024-1038.
32. Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005; 310: 306-310.
33. Wang L, Jin Q, Lee JE, Su IH, Ge K. Histone H3K27 methyltransferase Ezh2 represses Wnt genes to facilitate adipogenesis. Proc Natl Acad Sci USA 2010; 107: 7317-7322.
34. Nightingale KP, Gendreizig S, White DABradbury C, Hollfelder F, Turner BM. Crosstalk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. J Biol Chem 2007; 282: 4408-4416.
35. Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, Huebert DJ et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 2005; 120: 169-181.
36. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007; 39: 311-318.
37. Kim TH, Barrera LO, Zheng M, Qu C, Singer MA, Richmond TA et al. A highresolution map of active promoters in the human genome. Nature 2005; 436: 876-880.
38. Jeong EY, Kim S, Jung S, Kim G, Son H, Lee DH et al. Enhancement of IGF-2- induced neurite outgrowth by IGF-binding protein-2 and osteoglycin in SH-SY5Y human neuroblastoma cells. Neurosci Lett 2013; 548: 249-254.
39. Can A, Schulze TG, Gould TD. Molecular actions and clinical pharmacogenetics of lithium therapy. Pharmacol Biochem Behav 2014; 123C: 3-16.
40. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH et al. The moodstabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999; 72: 879-882.
41. Wang JF, Shao L, Sun X, Young LT. Glutathione S-transferase is a novel target for mood stabilizing drugs in primary cultured neurons. J Neurochem 2004; 88: 1477-1484.
42. Yu Z, Ono C, Kim HB, Komatsu H, Tanabe Y, Sakae N et al. Four mood stabilizers commonly induce FEZ1 expression in human astrocytes. Bipolar Disord 2011; 13: 486-499.
43. Sugawara H, Iwamoto K, Bundo M, Ishiwata M, Ueda J, Kakiuchi C et al. Effect of mood stabilizers on gene expression in lymphoblastoid cells. J Neural Transm 2010; 117: 155-164.
44. Youngs RM, Chu MS, Meloni EG, Naydenov A, Carlezon WA Jr., Konradi C. Lithium administration to preadolescent rats causes long-lasting increases in anxiety-like behavior and has molecular consequences. J Neurosci 2006; 26: 6031-6039.
45. Bosetti F, Bell JM, Manickam P. Microarray analysis of rat brain gene expression after chronic administration of sodium valproate. Brain Res Bull 2005; 65: 331-338.
46. Bosetti F, Seemann R, Bell JM, Zahorchak R, Friedman E, Rapoport SI et al. Analysis of gene expression with cDNA microarrays in rat brain after 7 and 42 days of oral lithium administration. Brain Res Bull 2002; 57: 205-209.
47. McQuillin A, Rizig M, Gurling HM. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet Genomics 2007; 17: 605-617.
48. Noga JT, Vladar K, Torrey EF. A volumetric magnetic resonance imaging study of monozygotic twins discordant for bipolar disorder. Psychiatry Res 2001; 106: 25-34.
49. Bertolino A, Frye M, Callicott JH, Mattay VS, Rakow R, Shelton-Repella J et al. Neuronal pathology in the hippocampal area of patients with bipolar disorder: A study with proton magnetic resonance spectroscopic imaging. Biol Psychiatry 2003; 53: 906-913.
50. Colla M, Schubert F, Bubner M, Heidenreich JO, Bajbouj M, Seifert F et al. Glutamate as a spectroscopic marker of hippocampal structural plasticity is elevated in long-term euthymic bipolar patients on chronic lithium therapy and correlates inversely with diurnal cortisol. Mol Psychiatry 2009; 14: 647.
51. Giakoumatos CI, Nanda P, Mathew IT, Tandon N, Shah J, Bishop JR et al. Effects of lithium on cortical thickness and hippocampal subfield volumes in psychotic bipolar disorder. J Psychiatr Res 2015; 61: 180-187.
52. Nugent AC, Carlson PJ, Bain EE, Eckelman W, Herscovitch P, Manji H et al. Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. J Psychopharmacol 2013; 27: 894-902.
53. Ruzicka WB, Subburaju S, Benes FM. Circuit- And diagnosis-specific DNA methylation changes at gamma-aminobutyric acid-related genes in postmortem human hippocampus in schizophrenia and bipolar disorder. JAMA Psychiatry 2015; 72: 541-551.
54. Torrey EF, Barci BM, Webster MJ, Bartko JJ, Meador-Woodruff JH, Knable MB. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 2005; 57: 252-260.
55. Knable MB, Barci BM, Webster MJ, Meador-Woodruff J, Torrey EF. Stanley Neuropathology C. Molecular abnormalities of the hippocampus in severe psychiatric illness: Postmortem findings from the Stanley Neuropathology Consortium. Mol Psychiatry 2004; 9: 544.
56. Du J, Creson TK, Wu LJ, Ren M, Gray NA, Falke C et al. The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci 2008; 28: 68-79.
57. Walz JC, Frey BN, Andreazza AC, Cereser KM, Cacilhas AA, Valvassori SS et al. Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. J Psychiatr Res 2008; 42: 416-421.
58. Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G et al. The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 2005; 25: 4493-4502.
59. Ahmed RR, Holler CJ, Webb RL, Li F, Beckett TL, Murphy MP. BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem 2010; 112: 1045-1053.
60. Azkona G, Amador-Arjona A, Obradors-Tarrago C, Varea E, Arque G, Pinacho R et al. Characterization of a mouse model overexpressing beta-site APP-cleaving enzyme 2 reveals a new role for BACE2. Genes Brain Behav 2010; 9: 160-172.
61. Beyer AS, von Einem B, Schwanzar D, Keller IE, Hellrung A, Thal DR et al. Engulfment adapter PTB domain containing 1 interacts with and affects processing of the amyloid-beta precursor protein. Neurobiol Aging 2012; 33: 732-743.
62. Santoro ML, Ota VK, Stilhano RS, Silva PN, Santos CM, Diana MC et al. Effect of antipsychotic drugs on gene expression in the prefrontal cortex and nucleus accumbens in the spontaneously hypertensive rat (SHR). Schizophr Res 2014; 157: 163-168.
63. Winden KD, Karsten SL, Bragin A, Kudo LC, Gehman L, Ruidera J et al. A systems level, functional genomics analysis of chronic epilepsy. PLoS One 2011; 6: E20763.
64. Guo M, Lu XY. Leptin receptor deficiency confers resistance to behavioral effects of fluoxetine and desipramine via separable substrates. Transl Psychiatry 2014; 4: E486.
65. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Weight gain and serum leptin levels in patients on lithium treatment. Neuropsychobiology 2002; 46: 67-69.
66. Gergerlioglu HS, Savas HA, Celik A, Savas E, Yumru M, Tarakcioglu M et al. Atypical antipsychotic usage-related higher serum leptin levels and disabled lipid profiles in euthymic bipolar patients. Neuropsychobiology 2006; 53: 108-112.
67. Himmerich H, Koethe D, Schuld A, Yassouridis A, Pollmacher T. Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. Psychopharmacology (Berl) 2005; 179: 447-451.
68. McIntyre RS, Mancini DA, Basile VS, Srinivasan J, Kennedy SH. Antipsychoticinduced weight gain: Bipolar disorder and leptin. J Clin Psychopharmacol 2003; 23: 323-327.
69. Soeiro-de-Souza MG, Gold PW, Brunoni AR, de Sousa RT, Zanetti MV, Carvalho AF et al. Lithium decreases plasma adiponectin levels in bipolar depression. Neurosci Lett 2014; 564: 111-114.
70. Tsai SY, Chung KH, Wu JY, Kuo CJ, Lee HC, Huang SH. Inflammatory markers and their relationships with leptin and insulin from acute mania to full remission in bipolar disorder. J Affect Disord 2012; 136: 110-116.
71. Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999; 53: 230-232.